|
1
|
Menna P, Recalcati S, Cairo G and Minotti
G: An introduction to the metabolic determinants of anthracycline
cardiotoxicity. Cardiovasc Toxicol. 7:80–85. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Barry E, Alvarez JA, Scully RE, Miller TL
and Lipshultz SE: Anthracycline-induced cardiotoxicity: Course,
pathophysiology, prevention and management. Expert Opin
Pharmacother. 8:1039–1058. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jang WJ, Choi DY and Jeon IS: Vascular
endothelial dysfunction after anthracyclines treatment in children
with acute lymphoblastic leukemia. Korean J Pediatr. 56:130–134.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Truong J, Yan AT, Cramarossa G and Chan
KK: Chemotherapy-induced cardiotoxicity: Detection, prevention and
management. Can J Cardiol. 30:869–878. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Spagnuolo RD, Recalcati S, Tacchini L and
Cairo G: Role of hypoxia-inducible factors in the
dexrazoxane-mediated protection of cardiomyocytes from
doxorubicin-induced toxicity. Br J Pharmacol. 163:299–312. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Guo R, Lin J, Xu W, Shen N, Mo L, Zhang C
and Feng J: Hydrogen sulfide attenuates doxorubicin-induced
cardiotoxicity by inhibition of the p38 MAPK pathway in H9c2 cells.
Int J Mol Med. 31:644–650. 2013.PubMed/NCBI
|
|
7
|
Gu J, Hu W and Zhang DD: Resveratrol, a
polyphenol phytoalexin, protects against doxorubicin-induced
cardiotoxicity. J Cell Mol Med. 19:2324–2328. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Karimi G, Ramezani M and Abdi A:
Protective effects of lycopene and tomato extract against
doxorubicin-induced cardio-toxicity. Phytother Res. 19:912–914.
2005. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Polhemus DJ and Lefer DJ: Emergence of
hydrogen sulfide as an endogenous gaseous signaling molecule in
cardiovascular disease. Circ Res. 114:730–737. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang Y, Tang ZH, Ren Z, Qu SL, Liu MH,
Liu LS and Jiang ZS: Hydrogen sulfide, the next potent preventive
and therapeutic agent in aging and age-associated diseases. Mol
Cell Biol. 33:1104–1113. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Huang YE, Tang ZH, Xie W, Shen XT, Liu MH,
Peng XP, Zhao ZZ, Nie DB, Liu LS and Jiang ZS: Endogenous hydrogen
sulfide mediates the cardioprotection induced by ischemic
post-conditioning in the early reperfusion phase. Exp Ther Med.
4:1117–1123. 2012.PubMed/NCBI
|
|
12
|
Polhemus DJ, Calvert JW, Butler J and
Lefer DJ: The cardioprotective actions of hydrogen sulfide in acute
myocardial infarction and heart failure. Scientifica (Cairo).
2014:7686072014.
|
|
13
|
Li C, Hu M, Wang Y, Lu H, Deng J and Yan
X: Hydrogen sulfide preconditioning protects against myocardial
ischemia/reperfusion injury in rats through inhibition of
endo/sarcoplasmic reticulum stress. Int J Clin Exp Pathol.
8:7740–7751. 2015.PubMed/NCBI
|
|
14
|
Sahu BD, Mahesh Kumar J and Sistla R:
Baicalein, a Bioflavonoid, Prevents Cisplatin-Induced Acute Kidney
Injury by Up-RegulatingAntioxidant Defenses and Down-Regulating the
MAPKs and NF-κB Pathways. PLoS One. 10:e01341392015. View Article : Google Scholar
|
|
15
|
Liu MH, Yuan C, He J, Tan TP, Wu SJ, Fu
HY, Liu J, Yu S, Chen YD, Le QF, Tian W, Hu HJ, Zhang Y and Lin XL:
Resveratrol protects PC12 cells from high glucose-induced
neurotoxicity via PI3K/Akt/FoxO3a pathway. Cell Mol Neurobiol.
35:513–522. 2015. View Article : Google Scholar
|
|
16
|
Wood ZA, Poole LB and Karplus PA:
Peroxiredoxin evolution and the regulation of hydrogen peroxide
signaling. Science. 300:650–653. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Poynton RA and Hampton MB: Peroxiredoxins
as biomarkers of oxidative stress. Biochim Biophys Acta.
1840:906–912. 2014. View Article : Google Scholar
|
|
18
|
Jeong HJ, Jeong HW, Song SS, Kang JW, Seo
JH, Lee YH, Lee KS and Kim DW: Upregulation of peroxiredeoxin III
in the hippocampus of acute immobilization stress model rats and
the Foxo3a-dependent expression in PC12 cells. Cell Mol Neurobiol.
31:1041–1046. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nemoto S, Combs CA, French S, Ahn BH,
Fergusson MM, Balaban RS and Finkel T: The mammalian
longevity-associated gene product p66shc regulates mitochondrial
metabolism. J Biol Chem. 281:10555–10560. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chae HZ, Kim HJ, Kang SW and Rhee SG:
Characterization of three isoforms of mammalian peroxiredoxin that
reduce peroxides in the presence of thioredoxin. Diabetes Res Clin
Pract. 45:101–112. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Matsushima S, Ide T, Yamato M, Matsusaka
H, Hattori F, Ikeuchi M, Kubota T, Sunagawa K, Hasegawa Y, Kurihara
T, et al: Overexpression of mitochondrial peroxiredoxin-3 prevents
left ventricular remodeling and failure after myocardial infarction
in mice. Circulation. 113:1779–1786. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chang TS, Cho CS, Park S, Yu S, Kang SW
and Rhee SG: Peroxiredoxin III, a mitochondrion-specific
peroxidase, regulates apoptotic signaling by mitochondria. J Biol
Chem. 279:41975–41984. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kimura H: Hydrogen sulfide: its
production, release and functions. Amino Acids. 41:113–121. 2011.
View Article : Google Scholar
|
|
24
|
Guo R, Wu K, Chen J, Mo L, Hua X, Zheng D,
Chen P, Chen G, Xu W, Feng J, et al: Exogenous hydrogen sulfide
protects against doxorubicin-induced inflammation and cytotoxicity
by inhibiting p38MAPK/NFkappaB pathway in H9c2 cardiac cells. Cell
Physiol Biochem. 32:1668–1680. 2013.
|
|
25
|
Wang X, Wang XL, Chen HL, Wu D, Chen JX,
Wang XX, Li RL, He JH, Mo L, Cen X, et al: Ghrelin inhibits
doxorubicin cardio-toxicity by inhibiting excessive autophagy
through AMPK and p38-MAPK. Biochem Pharmacol. 88:334–350. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ji Y, Pang QF, Xu G, Wang L, Wang JK and
Zeng YM: Exogenous hydrogen sulfide postconditioning protects
isolated rat hearts against ischemia-reperfusion injury. Eur J
Pharmacol. 587:1–7. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Osipov RM, Robich MP, Feng J, Liu Y,
Clements RT, Glazer HP, Sodha NR, Szabo C, Bianchi C and Sellke FW:
Effect of hydrogen sulfide in a porcine model of myocardial
ischemia-reperfusion: Comparison of different administration
regimens and characterization of the cellular mechanisms of
protection. J Cardiovasc Pharmacol. 54:287–297. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sodha NR, Clements RT, Feng J, Liu Y,
Bianchi C, Horvath EM, Szabo C and Sellke FW: The effects of
therapeutic sulfide on myocardial apoptosis in response to
ischemia-reperfusion injury. Eur J Cardiothorac Surg. 33:906–913.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pan TT, Feng ZN, Lee SW, Moore PK and Bian
JS: Endogenous hydrogen sulfide contributes to the cardioprotection
by metabolic inhibition preconditioning in the rat ventricular
myocytes. J Mol Cell Cardiol. 40:119–130. 2006. View Article : Google Scholar
|
|
30
|
Bian JS, Yong QC, Pan TT, Feng ZN, Ali MY,
Zhou S and Moore PK: Role of hydrogen sulfide in the
cardioprotection caused by ischemic preconditioning in the rat
heart and cardiac myocytes. J Pharmacol Exp Ther. 316:670–678.
2006. View Article : Google Scholar
|
|
31
|
Song IS, Kim HK, Jeong SH, Lee SR, Kim N,
Rhee BD, Ko KS and Han J: Mitochondrial peroxiredoxin III is a
potential target for cancer therapy. Int J Mol Sci. 12:7163–7185.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hattori F, Murayama N, Noshita T and
Oikawa S: Mitochondrial peroxiredoxin-3 protects hippocampal
neurons from excitotoxic injury in vivo. J Neurochem. 86:860–868.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Betge S, Lutz K, Roskos M and Figulla HR:
Oral treatment with probucol in a pharmacological dose has no
beneficial effects on mortality in chronic ischemic heart failure
after large myocardial infarction in rats. Eur J Pharmacol.
558:119–127. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jain AK and Mehra NK: Challenges and
Opportunities. Curr Pharm Des. 21:4441–4455. 2015. View Article : Google Scholar
|
|
35
|
Xi L, Zhu SG, Hobbs DC and Kukreja RC:
Identification of protein targets underlying dietary
nitrate-induced protection against doxorubicin cardiotoxicity. J
Cell Mol Med. 15:2512–2524. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Schwarzer M, Osterholt M, Lunkenbein A,
Schrepper A, Amorim P and Doenst T: Mitochondrial reactive oxygen
species production and respiratory complex activity in rats with
pressure overload-induced heart failure. J Physiol. 592:3767–3782.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Münzel T, Gori T, Keaney JF Jr, Maack C
and Daiber A: Pathophysiological role of oxidative stress in
systolic and diastolic heart failure and its therapeutic
implications. Eur Heart J. 36:2555–2564. PubMed/NCBI
|
|
38
|
Zuo L, Chuang CC and Hemmelgarn BT:
Defining the function of ROS and NO. J Appl Physiol. 119:944–951.
2015. View Article : Google Scholar
|
